| Annovis Bio (NYSE American: ANVS) Receives Institutional Review Board Approval to Initiate 15 Site Phase 2 Study in 68 Parkinson’s and Alzheimer’s Patients |
| |
|
Annovis Bio (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, reported that it has received Central Institutional Review Board (IRB) approval to begin its Phase 2 clinical study in early PD and early AD patients at 15 sites across the US.
Why It Matters: An IRB is a committee that applies research ethics by reviewing the methods proposed for research to ensure that they are ethical. Such boards are formally designated to approve or reject, monitor, and review biomedical and behavioral research involving humans. The purpose of the IRB is to assure that appropriate steps are taken to protect the rights and welfare of humans participating as subjects in a research study.
Key Quote: “We are excited to receive IRB approval to move forward with this Phase 2 study in PD and AD.” – Dr. Maria Maccecchini, CEO
The Backstory: Headquartered in Berwyn, Pennsylvania, Annovis Bio is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). We believe that we are the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. We expect our treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. We have an ongoing Phase 2a study in AD patients and plan to commence a second Phase 2a study in PD and AD patients.
Disclosure
Annovis (ANVS) is a client of RedChip Companies, Inc. ANVS agreed to pay RedChip Companies, Inc. a $8,500 monthly cash fee, beginning in February 2020, for RedChip investor awareness services and consulting services.
|
|
| |
|
| Digital Ally (NASDAQ: DGLY) Awarded Notable Contract in Wake of Increased Demand for Body Cameras and In-Car Systems |
| |
|
Digital Ally (NASDAQ: DGLY), which develops, manufactures and markets advanced video recording products and other critical safety products for law enforcement, emergency management, fleet safety and security, announced it has received a notable purchase order from Danville Police Department (Danville, IL) for 26 FirstVu HD body cameras, 16 DVM-800 in-car systems and 23 VuLink® auto-activation devices.
Key Quote: “The call for increased transparency between the public and police officers continues to be a driving force in the demand for body cams and in-car systems. We are confident our technology will aid in this increased transparency. Digital Ally looks forward to a great relationship with the Danville PD and the community it serves.” – Stan Ross, CEO
Backstory: Headquartered in Lenexa, Kansas, Digital Ally specializes in the design and manufacturing of the highest quality video recording equipment and video analytic software. Digital Ally pushes the boundaries of technology in industries such as law enforcement, emergency management, fleet safety and security. Digital Ally’s complete product solutions include vehicle and body cameras, flexible software storage, automatic recording technology and various critical safety products. These products work seamlessly together and are simple to install and operate. Digital Ally products are sold by domestic direct sales representatives and international distributors worldwide.
Disclosure
Digital Ally, Inc. (DGLY) is a client of RedChip Companies, Inc. DGLY agreed to pay RedChip Companies, Inc., a $7,500 monthly cash fee, beginning in September 2017, for RedChip investor awareness services.
|
|
| |
|
| Esports Entertainment (NASDAQ: GMBL) Partners with Allied Esports to Launch Inaugural VIE.gg CS:GO Legend Series Tournament |
| |
|
Esports Entertainment Group (Nasdaq: GMBL), a licensed online gambling company with a focus on esports wagering and 18+ gaming, has signed a licensing and sponsorship agreement with Allied Esports, a subsidiary of Allied Esports Entertainment, Inc. (NASDAQ: AESE), for the inaugural VIE.gg Counter-Strike: Global Offensive (“CS:GO”) Legend Series tournament beginning Monday, August 31, 2020.
Why It Matters: The VIE.gg CS:GO Legend Series will feature 12 teams from multiple European countries competing online for €50,000 in total prize money. The 5v5 tournament, which will be offered to customers on the VIE.gg platform, will be produced by Allied Esports from its HyperX Esports Studio in Hamburg, Germany and broadcast live on Twitch.tv/AlliedEsports with a lineup of professional casters and analysts.
Key Quote: “Title sponsorship places the VIE.gg brand front and center for teams, fans and influencers alike, further accelerating user adoption of the VIE.gg platform.” – Grant Johnson, CEO
The Backstory: Esports Entertainment Group is a licensed online gambling company with a specific focus on esports wagering and 18+ gaming. The Company holds a license to conduct online gambling and 18+ gaming on a global basis in Malta and Curacao, Kingdom of the Netherlands and is able to accept wagers from over 149 jurisdictions including Canada, Japan, Germany and South Africa. Esports Entertainment offers fantasy, pools, fixed odds and exchange style wagering on esports events in a licensed, regulated and secure platform to the global esports audience at vie.gg. In addition, Esports Entertainment intends to offer users from around the world the ability to participate in multi-player mobile and PC video game tournaments for cash prizes. Esports Entertainment is led by a team of industry professionals and technical experts from the online gambling and the video game industries, and esports.
Disclosure
Esports Entertainment Group, Inc. (GMBL) is a client of RedChip Companies, Inc. GMBL agreed to pay RedChip Companies, Inc. a $4,000 monthly cash fee, beginning in June 2018, and 225,000 shares of Rule 144 stock for RedChip investor awareness services.
|
|
| |
|
| Document Security Systems (NYSE American: DSS) Announces Multi-Year Contract Valued at $6 Million Per Annum with One of World’s Largest Retailers |
| |
|
Document Security Systems (NYSE American: DSS), a multinational company operating businesses focused on brand protection technology, blockchain security, direct marketing, healthcare, real estate, and securitized digital assets, announced its Premier Packaging Corp. (Premier) subsidiary signed a three-year contract with one of the world’s largest retailers to supply photo mailing envelopes and folding cartons for prints, posters, canvas decors, photo books, passport photos, and business printing. The contract is valued at approximately $6 million per year and may be renewed for a fourth year.
Why It Matters: Production on this contract will begin in the third quarter of 2020. Finished goods will ship to the customer’s more than 9000 locations. The retailer expects to open an additional 550 stores over the next 12 months, which will potentially increase the value of the contract.
Key Quote: “Our customer’s commitment to Premier demonstrates that the investments we have made into our business strategy are starting to show. These resources are the foundation and position this division for substantial growth.” – Jason Grady, COO
The Backstory: DSS is a multinational company operating businesses focused on brand protection technology, blockchain security, direct marketing, healthcare, real estate, and securitized digital assets. Its business model is based on a distribution sharing system in which shareholders will receive shares in its subsidiaries as DSS strategically spins them out into IPOs. Its historic business revolves around counterfeit deterrent and authentication technologies, smart packaging, and consumer product engagement. DSS is led by its Chairman and largest shareholder, Mr. Fai Chan, a highly successful global business veteran of more than 40 years specializing in corporate transformation while managing risk. He has successfully restructured more than 35 corporations with a combined value of $25 billion.
Disclosure
Document Securities Systems (DSS) is a client of RedChip Companies, Inc. DSS agreed to pay RedChip Companies, Inc. 21,000 shares of DSS Rule 144 stock for 14 months of service, beginning June 2020.
|
|
| |
|
| Recruiter.com (NASDAQ: RCRT) Announces Results of June 2020 Recruiter Index Survey As Seen on CNBC |
| |
|
Recruiter.com (NASDAQ: RCRT), a leading hiring platform for the world's largest network of recruiters, presented the results of the Recruiter Index® for June 2020 live on CNBC on 6/29/20.
Why it Matters: For the first time since the Recruiter Index® began surveying recruiters in April, the majority of survey respondents — 51.4 percent — said they expect their job requirement loads to improve over the next 30 days. Additionally, more recruiters than ever say COVID-19 is having little or no impact on their recruiting activities.
Key Quote: “Recruiter.com has been tracking recruiter sentiment and confidence since the beginning of the pandemic, and the latest results continue the positive trends we identified in previous iterations of the survey.” – Evan Sohn, CEO
The Backstory: Recruiter.com is a hiring platform for the world's largest network of recruiters, empowering businesses to recruit specialized talent faster with virtual teams of recruiters and AI job-matching technology.
Disclosure
Recruiter.com (RCRT) is a client of RedChip Companies, Inc. RCRT agreed to pay RedChip Companies, Inc. 9,000 shares of RCRT common stock and a $7,500 monthly cash fee, beginning in June 2020 for RedChip investor awareness services.
|
|
| |
|
| COMSovereign Holding (OTCQB: COMS) Extends 4G LTE/5G Networking Solution Portfolio with Closing of Virtual Network Communications Acquisition |
| |
|
COMSovereign Holding Corp. (OTCQB: COMS), a U.S.-based pure-play developer of 5G connectivity and data transmission systems, announced that it has completed the acquisition of Virtual Network Communications, Inc. ("VNC"), a developer of fixed and mobile broadband communications solutions for public and private wireless networks operated by commercial, enterprise, government and defense customers.
Why It Matters: The closing of this latest acquisition significantly expands COMSovereign's IP and product portfolio to include telecom network access systems including both 4G LTE/Advanced and 5G capable radio equipment. Additionally, VNC has virtualized and patented an entire LTE Advanced network core solution that has the potential to dramatically reduce the costs of traditional telecom network backbone equipment. VNC has also developed and is currently selling a rapidly deployable LTE network system that is both man-portable and can be combined with the tethered aerostats and drone systems produced by COMSovereign's Drone Aviation subsidiary to provide telecom network access in nearly any location in minimum time.
Key Quote: “VNC's proprietary virtualized core technology significantly advances our ability to provide network operators with a complete range of wireless technologies from the network edge to backhaul. This enables operators to quickly accelerate their strategic 4G LTE and 5G network modernization and upgrade programs.” – Dan Hodges, Chairman & CEO
The Backstory: COMSovereign Holding Corp. (OTCQB: COMS) has assembled a portfolio of communications technology companies with combined capabilities and the objective of enabling connectivity across the entire data transmission spectrum. Through strategic acquisitions and organic research and development efforts, COMSovereign is seeking to become a U.S.-based pure-play communications provider able to provide LTE Advanced and 5G-NR telecom solutions to network operators and enterprises.
Disclosure
COMSovereign Holding Corp. (COMS) is a client of RedChip Companies, Inc. COMS agreed to pay RedChip Companies, Inc. a $10,000 monthly cash fee for RedChip investor awareness services, beginning upon certain milestone achievements, including uplisting to a major exchange. COMS also agreed to issue RedChip Companies Inc. a one-time grant of 55,000 shares of common stock in May 2020.
|
|
| |
|
| Nemaura Medical (NASDAQ: NMRD) Evaluates New Applications for Continuous Lactate Monitoring Using its BEAT™ Platform |
| |
|
Nemaura Medical (NASDAQ: NMRD), a medical technology company commercializing sugarBEAT®, a non-invasive and flexible continuous glucose monitor (CGM), together with BEAT®diabetes, a health subscription service designed to help people with diabetes and prediabetes to better manage their condition through personalized lifestyle coaching, issued a presentation outlining potential new applications for monitoring disease progression in Covid-19 patients using Continuous Lactate Monitoring (CLM).
Why it Matters: The Company has previously discussed the market for athletic performance monitoring using its non-invasive continuous lactate monitor (CLM), and based on recently published independent clinical evaluations, the measurement of blood lactic acid has been established as an indicator for disease progression in Covid-19 patients. The company has issued a presentation on this subject, which can be found here: https://nemauramedical.com/wp-content/uploads/2020/07/BEAT-CLM-in-Covid19-July-2020-1.
Backstory: Nemaura Medical is a medical technology company developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, and proBEAT™. sugarBEAT®, a CE mark approved Class IIb medical device, is a non-invasive and flexible CGM providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse and prevent the onset of diabetes. Nemaura is planning to submit a PMA application for sugarBEAT® during the second quarter of 2020 for FDA review of this device under medical device regulations. proBEAT™ comprises a non-invasive glucose monitor and a digital healthcare subscription service and is due to be launched in the US as a general wellness product.
Disclosure
Nemaura Medical (NMRD) is a client of RedChip Companies. NMRD agreed to pay RedChip a monthly cash fee of $6,000 and 15,000 shares of Rule 144 stock for three months of investor awareness services.
|
|
| |
|
| 1847 Holdings (OTC: EFSH) Announces Asien’s Appliance Subsidiary Generated $1.1 Million in Sales in June |
| |
|
1847 Holdings (OTC: EFSH), a unique publicly traded holding company platform that acquires lower-middle market, American companies at attractive valuations, today announced its Asien’s Appliance subsidiary, a California-based appliance retailer, generated approximately $1.1 million in total sales in June 2020, up 21% over June 2019 total sales.
Why it Matters: The household appliance market in the US is forecasted to exceed $21 billion in 2020 and is expected to grow at a CAGR of 13.7%, reaching $40 billion in 2025, according to data from Statista.
Key Quote: “We’re extremely pleased with the strong performance of Asien’s in its first month since the acquisition was completed, with sales growth more than doubling when compared to the year-over-year growth rate for the first half of 2020.” – Ellery Roberts, CEO
Backstory: 1847 Holdings operates American companies it acquires at attractive valuations, leveraging its management team’s extensive experience gained at leading investment firms, such as Colony Capital, Lazard Freres and Saunders, Karp & Megrue, to grow operations and create value. 1847 Holdings seeks to generate returns for shareholders in the future through consistent, annual distributions of operating subsidiary income and capital appreciation resulting from the timely sale of operating subsidiaries.
Disclosure
1847 Holdings (EFSH) is a client of RedChip Companies, Inc. EFSH agreed to pay RedChip Companies, Inc. a $8,500 monthly cash fee, beginning in November 2019, and 100,000 restricted common shares of EFSH stock for 12 months of RedChip investor awareness services.
|
|
| |
|
| SOBR Safe (OTC: SOBR) Further Bolsters Commercialization Capabilities with Addition of New Product Development Engineer |
| |
|
SOBR Safe (OTC: SOBR), developers of the patented non-invasive alcohol detection system SOBR™Check, announced today that it has significantly enhanced its in-house technology expertise with the addition of Katia Benson as New Product Development Engineer.
Why it Matters: Benson will serve as SOBRCheck Program Manager, shepherding the solution from current pilot test phase to anticipated commercial sales in First Quarter 2021. She will also lead new technology development, sourcing and integrating other potentially disruptive detection solutions.
Key Quote: “As we continue to supplement this truly world-class team, cultural fit will be as central to our success as product performance.” – Kevin Moore, CEO
Backstory: SOBR Safe has developed and patented a non-invasive alcohol sensing system – SOBR™Check. SOBRCheck is a potentially disruptive solution in alcohol consumption detection - a touch-based technology with anticipated applications in school buses, commercial trucking fleets, facility access control and more. Across industries, the headlines are consistent: alcohol is a clear and present danger - impaired operation destroys lives, families, and companies alike. SOBR Safe's mission is to eliminate the destructive impact of alcohol on our roadways and workplaces…with just the touch of a finger.
Disclosure
SOBRSafe (SOBR) is a client of RedChip Companies, Inc. SOBR agreed to pay RedChip Companies, Inc., a $4,000 monthly cash fee, beginning in April 2020, for the first three months, $8,000 per month for month four through six for RedChip investor awareness services. The Company will pay RC 5,000 shares of Rule 144 Stock when the stock price reaches $5.00, and another 5,000 shares of Rule 144 Stock when the stock price reaches $8.00.
|
|
| |
|
| CytoDyn (OTCQB: CYDY) Provides Update on BLA Submission for HIV Therapy |
| |
|
CytoDyn (OTCQB: CYDY), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced it has received a Refusal to File letter from the U.S. Food and Drug Administration (“FDA”) regarding its Biologics License Application (“BLA”) for leronlimab as a combination therapy with HAART for highly treatment experienced HIV patients. CytoDyn is confident it can provide all information requested by the FDA.
Why it Matters: CytoDyn previously announced it submitted all remaining parts of its BLA for leronlimab on May 11, 2020. Pursuant to FDA guidelines, CytoDyn informed the FDA it had submitted a complete BLA for rolling review. In its comments on May 13, CytoDyn stated as a next step after receiving the BLA, the FDA would start reviewing the BLA for completeness and would make a filing decision. The FDA has informed the Company its BLA does not contain certain information needed to complete a substantive review and therefore, the FDA will not file the BLA at this time. CytoDyn intends to request a Type A meeting with the FDA to discuss its request for additional information. The FDA’s request does not require any additional clinical trials to be conducted, rather the Company will conduct additional analysis of completed trials.
Key Quote: “We are 100% committed and confident we can provide the necessary information to the FDA as soon as possible. No additional trials will be required and all the information the FDA has requested is obtainable.” – Nader Pourhassan, Ph.D., President and CEO
Backstory: CytoDyn is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a critical role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor metastasis and immune-mediated illnesses, such as GvHD and NASH. CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients. CytoDyn filed its BLA in April 2020 to seek FDA approval for leronlimab as a combination therapy for highly treatment experienced HIV patients, and submitted additional FDA requested clinical datasets on May 11, 2020. CytoDyn is also conducting a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients. CytoDyn plans to initiate a registration-directed study of leronlimab monotherapy indication. If successful, it could support a label extension. Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV. No drug-related serious site injection reactions reported in about 800 patients treated with leronlimab and no drug-related SAEs reported in patients treated with 700 mg dose of leronlimab. Moreover, a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients; some patients on leronlimab monotherapy have remained virally suppressed for more than five years. CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for the prevention of GvHD and a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer.
Disclosure
CytoDyn (CYDY) is a client of RedChip Companies, Inc. CYDY agreed to pay RedChip Companies, Inc., a $7,500 quarterly cash fee, beginning in May 2020, for RedChip investor awareness services. The CEO of RedChip Companies owns 3400 shares of CYDY.
|
|
| |
|
| Medalist Diversified REIT (NASDAQ: MDRR) Announces Series A Preferred Stock Cash Dividend |
| |
|
Medalist Diversified REIT (NASDAQ: MDRR), a Virginia-based real estate investment trust that specializes in acquiring, owning and managing value-add commercial real estate in the Southeast region of the U.S., today announced that its Board of Directors has authorized and the Company has declared a dividend for the 2nd quarter of 2020 on its 8.0% Series A Cumulative Redeemable Preferred Stock (the "Series A Preferred Stock") in the amount of $0.5000 per share (the "Series A Dividend").
The Series A Dividend will be payable in cash on July 24, 2020 to holders of record of Series A Preferred Stock as of July 22, 2020.
Backstory: Medalist Diversified REIT is a Virginia-based real estate investment trust that specializes in acquiring, owning and managing value-add commercial real estate in the Mid-Atlantic and Southeast regions. The Company’s strategy is to focus on value-add and opportunistic commercial real estate which is expected to provide an attractive balance of risk and returns. Medalist utilizes a rigorous, consistent and replicable process for sourcing and conducting due diligence of acquisitions. The Company seeks to maximize operating performance of current properties by utilizing a hands-on approach to property management while monitoring the middle market real estate markets in the southeast for acquisition opportunities and disposal of properties as considered appropriate.
Disclosure
Medalist Diversified REIT (MDRR) is a client of RedChip Companies, Inc. MDRR agreed to pay RedChip Companies, Inc. a monthly cash fee of $4,250 for four (4) months followed by a monthly cash fee of $8,500 for eight (8) months of RedChip investor awareness services, beginning in August 2019. The CEO of RedChip Companies owns 3358 shares of MDRR.
|
|
| |
|
| |
| Quote of the Week |
| |
"Small caps outperform not because of market capitalization alone but because the stocks in this category are least efficiently priced."
- James O'Shaughnessy, What Works on Wall Street |
|
|
|
|
|
|
|
| About RedChip |
| |
| RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on small-cap and mid-cap companies. Since 1992, RedChip has delivered concrete, measurable results for its clients through the most comprehensive service platform in the industry for small-cap and mid-cap companies. These services include a worldwide distribution network for its stock research written by analysts holding the CFA designation; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated over 2.3 million unique investor views; quarterly global online institutional and retail investor conferences that reach over 10,000 investors annually; "The RedChip Money Report" television show which airs in 100 million homes across the U.S. on The Family Channel; a weekly newsletter delivered to 60,000 investors; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. |
| |
| RedChip Disclosure |
| |
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that the RedChip Companies Inc. is an investor relations firm hired by certain Companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov and view RedChip’s Disclosures. |
|
| |
|
|
| |
|
|
Copyright © 2020 RedChip Companies, Inc. All Rights Reserved.
You are receiving this message because this email address has signed up to receive News Alerts.
|
|
|
|
|
| | | |
